<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039710</url>
  </required_header>
  <id_info>
    <org_study_id>CR109081</org_study_id>
    <secondary_id>75220795NAS1002</secondary_id>
    <nct_id>NCT05039710</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-75220795 in Japanese Participants</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 in Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of single subcutaneous&#xD;
      (SC) dose of JNJ-75220795 in Japanese participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">November 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent Signs and Symptoms/Adverse Events (AEs)</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Number of participants with treatment-emergent signs and symptoms/adverse events (including allergic reactions/hypersensitivity and local injection site reactions) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Treatment-emergent adverse events (TEAEs) are defined as AEs with onset or worsening on or after date of first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Vital Signs Abnormalities</measure>
    <time_frame>Baseline, Up to Day 168</time_frame>
    <description>Number of participants with change from baseline in vital signs abnormalities including body temperature (axillary), pulse, respiratory rate and blood pressure will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Clinical Laboratory Abnormalities</measure>
    <time_frame>Baseline, Up to Day 168</time_frame>
    <description>Number of participants with change from baseline in clinical laboratory abnormalities including hematology, serum chemistry and urinalysis will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Physical Examination Abnormalities</measure>
    <time_frame>Baseline, Up to Day 168</time_frame>
    <description>Number of participants with change from baseline in physical examination abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Baseline, Up to Day 168</time_frame>
    <description>Number of participants with change from baseline in ECG abnormalities will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Liver Fat Content Measured by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)</measure>
    <time_frame>From Baseline to Weeks 6, 12, 18, and 24</time_frame>
    <description>Percent change in liver fat content as measured by MRI-PDFF will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of JNJ-75220795</measure>
    <time_frame>Predose up to 48 hours postdose (up to Day 3)</time_frame>
    <description>Cmax of JNJ-75220795 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-75220795</measure>
    <time_frame>Predose up to 48 hours postdose (up to Day 3)</time_frame>
    <description>Tmax of JNJ-75220795 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-Life (t1/2) of JNJ-75220795</measure>
    <time_frame>Predose up to 48 hours postdose (up to Day 3)</time_frame>
    <description>t1/2 is defined as apparent elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve of JNJ-75220795 from Time Zero to Infinite time (AUC [0-Infinity])</measure>
    <time_frame>Predose up to 48 hours postdose (up to Day 3)</time_frame>
    <description>AUC (0-Infinity) is defined as the area under the plasma concentration versus time curve of JNJ-75220795 from time zero to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus Time Curve of JNJ-75220795 from Time Zero to Time of the Last Measurable Concentration (AUC [0-Last])</measure>
    <time_frame>Predose up to 48 hours postdose (up to Day 3)</time_frame>
    <description>AUC (0-Last) is defined as area under the plasma concentration versus time curve of JNJ-75220795 from time zero to time of the last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Apparent Clearance (CL/F) of JNJ-75220795</measure>
    <time_frame>Predose up to 48 hours postdose (up to Day 3)</time_frame>
    <description>CL/F is defined as total apparent clearance of JNJ-75220795.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of JNJ-75220795</measure>
    <time_frame>Predose up to 48 hours postdose (up to Day 3)</time_frame>
    <description>Vd/F is defined as apparent volume of distribution of JNJ-75220795.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Emergent Anti-drug Antibody (ADA)</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Number of participants with treatment emergent ADA will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Cohort 1: JNJ-75220795 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single subcutaneous (SC) dose of JNJ-75220795 Dose 1 or matching placebo on Day 1 in Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: JNJ-75220795 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single SC dose of JNJ-75220795 Dose 2 or matching placebo on Day 1 in Cohort 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-75220795</intervention_name>
    <description>JNJ-75220795 will be administered as SC injection.</description>
    <arm_group_label>Cohort 1: JNJ-75220795 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2: JNJ-75220795 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered as SC injection.</description>
    <arm_group_label>Cohort 1: JNJ-75220795 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2: JNJ-75220795 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with certain genetic predispositions to non-alcoholic fatty liver disease&#xD;
             (NAFLD) determined at screening&#xD;
&#xD;
          -  Presence of liver steatosis at screening&#xD;
&#xD;
          -  Participants on anti-hypertensive and/or lipid lowering medications and/or glucose&#xD;
             lowering medications must be on stable dose(s) for at least 4 weeks prior to screening&#xD;
&#xD;
          -  Body mass index between 18 kilograms per meter square (kg/m^2) and 40 kg/m^2&#xD;
             inclusive, and body weight stable defined as no more than 5 percent (%) body weight&#xD;
             loss or gain within 3 months prior to screening (based on participant's report) and no&#xD;
             more than 5% body weight loss or gain from screening to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to excipients&#xD;
&#xD;
          -  History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV)&#xD;
             positive, or other clinically active liver disease, or tests positive for HbsAg or&#xD;
             anti-HCV at screening. And/or history of human immunodeficiency virus (HIV) antibody&#xD;
             positive, or tests positive for HIV or syphilis at screening&#xD;
&#xD;
          -  Participants with clinical or biochemical (international normalized ratio [INR]&#xD;
             greater than [&gt;] 1.2, or platelet count less than [&lt;] lower limits of normal [LLN])&#xD;
             evidence of hepatic decompensation at screening or baseline&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) by Japanese eGFR formula below 60&#xD;
             milliliters per minute [mL/min] at screening&#xD;
&#xD;
          -  Thyroid stimulating hormone (TSH) levels, free triiodothyronine (FT3) and free&#xD;
             thyroxine (FT4) outside normal limits of the clinical laboratory's reference range at&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Souseikai Fukuoka Mirai Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporation Heishinkai ToCROM Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>160-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporation Heishinkai OCROM Clinic</name>
      <address>
        <city>Suita-city</city>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumida Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

